Enabling Faster Therapeutic Antibody Discovery Through AI/ML-Wet Lab Integration

Explore an innovative AI/ML platform that guides antibody design and accelerates the discovery of better antibody therapeutics in this 33-minute webinar. Learn how BigHat Biosciences integrates high-speed wet lab techniques with artificial intelligence and machine learning to create superior antibodies faster. Discover the potential of synthetic biology in developing safer and more effective antibody therapies for patients. Gain insights into the Milliner platform, which enables dynamic tracking and monitoring of laboratory and data generation processes. Understand how BigHat's automation strategy prioritizes early and flexible development, utilizing a cutting-edge technology stack. Examine the multi-tiered control systems that allow for close monitoring and optimization of the platform, extending to lab operations and documentation. Delve into the world of human-designed, next-generation antibodies and their potential as breakthrough therapeutics.

Intro
Synthetic biology in everyday life
Safer, more effective antibody therapies for patients using machine learning and synthetic biology
Human-designed, next-generation antibodies are becoming breakthrough therapeutics today
Better therapeutic antibodies faster with Al-guided antibody design and engineering
BigHat's Milliner platform integrates a high-speed wet lab with AI/ML to create better antibodies faster
Reccy Workflows enable dynamic tracking and monitoring of laboratory and data generation processes
BigHat automation features cutting-edge technology stack
BigHat automation strategy prioritizes early and flexible development
Multi-tiered controls enable close monitoring and optimization of BigHat's platform
Rigorous monitoring extends to lab operations and documentation